Former Google DeepMind Director brings over two decades of AI research expertise and industrial leadership to Genesis’ AI platform and high-performing research teams

BURLINGAME, Calif.: Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for the treatment of severe diseases, today announced the appointment of Aleksandra Faust, Ph.D., as Chief AI Officer.

Dr. Faust joins Genesis with more than 20 years of leadership experience in the AI and tech industries, developing machine learning (ML) for complex systems such as robotics and autonomous vehicles. She most recently served as Director of Research at Google DeepMind, overseeing foundational model learning research and contributing to Gemini and to generalist web agents, among many other key innovations in her tenure. In her previous roles, she co-founded reinforcement learning research at Google Brain, founded task and motion planning research in Robotics at Google, led machine learning for self-driving car planning and controls at Waymo, and was a principal investigator at Sandia National Laboratories.

“We are excited to welcome Aleksandra to our world-class team of scientists, engineers and innovators,” said Evan Feinberg, Ph.D., founder and CEO of Genesis. “As an established industry leader and pioneer in fundamental AI research across multiple complex domains, Aleksandra will play an instrumental role in elevating our GEMS platform’s suite of generative and predictive AI technologies.”

Dr. Faust earned a Ph.D. and a Master's degree in Computer Science from the University of New Mexico, and the University of Illinois at Urbana-Champaign, respectively. She has co-authored over 60 publications, the high impact of which is reflected in her h-index of 40, and her research has been featured in The New York Times and Forbes. Dr. Faust has also been recognized with numerous honors, including the IEEE Robotics and Automation Society Early Career Award and being named a Distinguished Alumna by the University of New Mexico School of Engineering.

“I am thrilled to join Genesis in its mission to usher in a new era of drug discovery with AI,” said Dr. Faust. “The company’s GEMS platform exemplifies how advanced machine learning can be synthesized with physics to enable the discovery of novel small molecule compounds that could produce breakthrough medicines for patients. I look forward to working with the talented Genesis team to push the boundaries of what is possible.”

About Genesis Therapeutics

Genesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), for small molecule drug discovery. GEMS integrates proprietary AI methods, including language models, diffusion models and physical simulation, to generate and optimize molecules for complex targets. Genesis has raised over $300 million from leading life science, tech, and AI-focused investors, and is building a therapeutics pipeline for a variety of high-impact targets. Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. For more information on Genesis, please visit the company’s website at www.genesistherapeutics.ai.

Fonte: Business Wire